Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Large-cell lymphomas: clinical and prognostic features.

R S Stein1, J P Greer, J M Flexner

  • 1Department of Medicine (Division of Hematology), Vanderbilt University Medical Center, Nashville, TN 37232.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|August 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma.

Leukemia·2016
Same author

Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

Six-month freedom from treatment failure is an important end point for acute GVHD clinical trials.

Bone marrow transplantation·2013
Same journal

Biology Over Monotherapy: Mature Results From European Organisation For Research and Treatment of Cancer 22033-26033 Reaffirm Molecular Stratification, Not Treatment Sequence, Defines Prognosis in Low-Grade Glioma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
See all related articles

This study on large-cell lymphomas found peripheral T-cell lymphoma (PTCL) has significantly poorer survival. More aggressive chemotherapy may improve outcomes for PTCL patients.

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • Large-cell lymphomas (LCL) encompass several subtypes with varying clinical behaviors.
  • Understanding the distinct features and prognoses of these subtypes is crucial for effective treatment.

Purpose of the Study:

  • To review and compare the clinical and pathological features of different large-cell lymphoma subtypes.
  • To identify prognostic factors influencing survival in patients with large-cell lymphomas.

Main Methods:

  • Retrospective review of 186 patients with large-cell lymphomas diagnosed between 1970 and 1986.
  • Categorization into large noncleaved-cell lymphoma (LNCCL), large-cleaved-cell lymphoma (LCCL), peripheral T-cell lymphoma (PTCL), and immunoblastic sarcoma of B cells (IBS-B).
  • Analysis of clinical features, pathological patterns, and survival data.

Related Experiment Videos

Main Results:

  • Subtypes showed differences in sex ratio, symptoms, extranodal disease, and adenopathy patterns.
  • Univariate analysis identified age, stage, marrow involvement, extranodal disease, B symptoms, elevated LDH, and diffuse pattern as unfavorable prognostic factors.
  • Peripheral T-cell lymphoma (PTCL) demonstrated significantly inferior survival (median 11 months) compared to other subtypes (median 46 months).
  • Immunoblastic sarcoma of B cells (IBS-B) did not show inferior survival compared to LNCCL or LCCL.

Conclusions:

  • The prognostic significance of nodular versus diffuse patterns was dependent on the specific lymphoma subtype.
  • Peripheral T-cell lymphoma (PTCL) is associated with poor prognosis, potentially linked to chemotherapy regimens.
  • More aggressive chemotherapy approaches may improve outcomes for PTCL patients.